title: Prehypertension and risk of cardiovascular disease in Chinese adults.
abstract: OBJECTIVE
  To examine the excess risks associated with prehypertension and absolute benefit of treatment.
  
  
  METHODS
  We conducted a prospective cohort study in 169 871 Chinese adults aged 40 years and older. Data on blood pressure and covariables were obtained at a baseline examination in 1991 and follow-up evaluation was conducted in 1999-2000.
  
  
  RESULTS
  Compared with normotension (<120/80 mmHg), prehypertension (120-139/80-89 mmHg) was significantly associated with an increased relative risk (95% confidence interval) of cardiovascular disease (CVD) incidence 1.34 (1.27, 1.42) and mortality 1.22 (1.15, 1.30), coronary disease incidence 1.32 (1.16, 1.50) and mortality 1.47 (1.23, 1.75), and stroke incidence 1.72 (1.59, 1.86) and mortality 1.67 (1.50, 1.86). The population-attributable risk associated with prehypertension was 10.6 and 7.1% for CVD incidence and mortality, 9.9 and 13.9% for coronary disease incidence and mortality, and 19.9 and 18.7% for stroke incidence and mortality. The optimal 5-year number-needed-to-treat to prevent a CVD event or death was 53 and 185, 17 and 51, and eight and 22 for prehypertension, stage 1 hypertension, and stage 2 hypertension, respectively. The optimal number-needed-to-treat to prevent a CVD event was significantly smaller in prehypertension patients with a history of CVD or diabetes (34 for incidence and 44 for mortality) compared with those without (115 for incidence and 352 for mortality).
  
  
  CONCLUSIONS
  Prehypertension was related to an increased risk of CVD. Treatment of prehypertension among patients with a history of CVD or diabetes was as beneficial as treatment of stage 1 hypertensive patients without a history of CVD or diabetes.
authors.affiliation: Department of Evidence Based Medicine, Cardiovascular Institute, Fu Wai Hospital of the Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. gudongfeng@vip.sina.com
authors.forename: Dongfeng
authors.initials: D
authors.lastname: Gu
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
authors.forename: Xigui
authors.initials: X
authors.lastname: Wu
authors.forename: Xiufang
authors.initials: X
authors.lastname: Duan
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Jones
authors.forename: Jian-feng
authors.initials: JF
authors.lastname: Huang
authors.forename: Chung-Shiuan
authors.initials: CS
authors.lastname: Chen
authors.forename: Ji-chun
authors.initials: JC
authors.lastname: Chen
authors.forename: Tanika N
authors.initials: TN
authors.lastname: Kelly
authors.forename: Paul K
authors.initials: PK
authors.lastname: Whelton
authors.forename: Jiang
authors.initials: J
authors.lastname: He
mesh_terms: D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000209:etiology*; D002681:China; D015331:Cohort Studies; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012306:Risk